b-AP15 - CAS 1009817-63-3
Catalog number:
1009817-63-3
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C22H17N3O6
Molecular Weight:
419.39
COA:
Inquire
Targets:
Deubiquitinase
Description:
b-AP15 is a deubiquitinases inhibitor for 19S proteasomes activity of Ub-AMC cleavage with IC50 of 2.1 μM.Not a general deubiquitinase inhibitor. Has minimal inhibition on recombinant and cytosolic nonproteasomal cysteine deubiquitinases.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
N/A
MSDS:
Inquire
1.Induction of tumor cell apoptosis by a proteasome deubiquitinase inhibitor is associated with oxidative stress.
Brnjic S1, Mazurkiewicz M, Fryknäs M, Sun C, Zhang X, Larsson R, D'Arcy P, Linder S. Antioxid Redox Signal. 2014 Dec 10;21(17):2271-85. doi: 10.1089/ars.2013.5322. Epub 2013 Oct 17.
AIMS: b-AP15 is a recently described inhibitor of the USP14/UCHL5 deubiquitinases (DUBs) of the 19S proteasome. Exposure to b-AP15 results in blocking of proteasome function and accumulation of polyubiquitinated protein substrates in cells. This novel mechanism of proteasome inhibition may potentially be exploited for cancer therapy, in particular for treatment of malignancies resistant to currently used proteasome inhibitors. The aim of the present study was to characterize the cellular response to b-AP15-mediated proteasome DUB inhibition.
2.Regulation of TRAIL-receptor expression by the ubiquitin-proteasome system.
Sarhan D1, D'Arcy P2, Lundqvist A3. Int J Mol Sci. 2014 Oct 14;15(10):18557-73. doi: 10.3390/ijms151018557.
The tumor necrosis factor (TNF)-related apoptosis-inducing ligand- receptor (TRAIL-R) family has emerged as a key mediator of cell fate and survival. Ligation of TRAIL ligand to TRAIL-R1 or TRAIL-R2 initiates the extrinsic apoptotic pathway characterized by the recruitment of death domains, assembly of the death-inducing signaling complex (DISC), caspase activation and ultimately apoptosis. Conversely the decoy receptors TRAIL-R3 and TRAIL-R4, which lack the pro-apoptotic death domain, function to dampen the apoptotic response by competing for TRAIL ligand. The tissue restricted expression of the decoy receptors on normal but not cancer cells provides a therapeutic rational for the development of selective TRAIL-mediated anti-tumor therapies. Recent clinical trials using agonistic antibodies against the apoptosis-inducing TRAIL receptors or recombinant TRAIL have been promising; however the number of patients in complete remission remains stubbornly low.
3.Deubiquitinases Modulate Platelet Proteome Ubiquitination, Aggregation, and Thrombosis.
Gupta N1, Li W1, McIntyre TM2. Arterioscler Thromb Vasc Biol. 2015 Dec;35(12):2657-66. doi: 10.1161/ATVBAHA.115.306054. Epub 2015 Oct 15.
OBJECTIVE: Platelets express a functional ubiquitin-proteasome system. Mass spectrometry shows that platelets contain several deubiquitinases, but whether these are functional, modulate the proteome, or affect platelet reactivity are unknown.
4.Simultaneous inhibition of deubiquitinating enzymes (DUBs) and autophagy synergistically kills breast cancer cells.
Vogel RI1, Coughlin K2, Scotti A3, Iizuka Y2, Anchoori R4,5, Roden RB4,5,6, Marastoni M3, Bazzaro M1,2. Oncotarget. 2015 Feb 28;6(6):4159-70.
Breast cancer is one of the leading causes of cancer death among women in the United States. Patients expressing the estrogen and progesterone receptor (ER and PR) and human epidermal growth factor 2 (HER-2) tumor markers have favorable prognosis and efficacious therapeutic options. In contrast, tumors that are negative for these markers (triple-negative) have a disproportionate share of morbidity and mortality due to lack of a validated molecular target. Deubiquitinating enzymes (DUBs) are a critical component of ubiquitin-proteasome-system degradation and have been shown to be differentially expressed and activated in a number of cancers, including breast, with their aberrant activity linked to cancer prognosis and clinical outcome. We evaluated the effect of the DUB inhibitors b-AP15 and RA-9 alone and in combination with early- and late-stage lysosomal inhibitors on cell viability in a panel of triple negative breast cancer (TNBC) cell lines.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Deubiquitinase Products


CAS 1572414-83-5 ML-323

ML-323
(CAS: 1572414-83-5)

CAS 1381291-36-6 USP7-IN-1

USP7-IN-1
(CAS: 1381291-36-6)

USP7-IN-1 is a novel selective and reversible inhibitor of USP7 with IC50 of 33 uM; less or no inhibition on USP5, USP8, Uch-L1, Uch-L3 and Caspase(IC50>200 ...

CAS 2645-32-1 PR-619

PR-619
(CAS: 2645-32-1)

CAS 1426944-49-1 HBX 19818

HBX 19818
(CAS: 1426944-49-1)

HBX 19818 exhibited a dose-dependent effect on USP7 activity. HBX 19,818 efficiently blocked labeling of USP7 but not that of USP8, USP5, USP10, CYLD, or UCH-L3...

CAS 1247825-37-1 USP7-USP47 inhibitor

USP7-USP47 inhibitor
(CAS: 1247825-37-1)

USP7/USP47 inhibitor(compound 14) is a selective USP7 (EC50= 0.42 μM)/USP47 (EC50= 1.0 μM) inhibitor but does not inhibit caspase 3, calpain 1, 20S proteasome, ...

CAS 1009817-63-3 b-AP15

b-AP15
(CAS: 1009817-63-3)

b-AP15 is a deubiquitinases inhibitor for 19S proteasomes activity of Ub-AMC cleavage with IC50 of 2.1 μM.Not a general deubiquitinase inhibitor. Has minimal in...

CAS 856243-80-6 Degrasyn

Degrasyn
(CAS: 856243-80-6)

Degrasyn, also known as WP1130, is a small molecule that specifically and rapidly down-regulates both wild-type and mutant Bcr/Abl protein without affecting bcr...

CAS 1991986-30-1 ML364

ML364
(CAS: 1991986-30-1)

ML364 is a small molecule, reversible inhibitor of the deubiquitinase USP2, that has an IC50 value of 1.1 µM in a fluorescence-based assay using di-ubiquitin su...

CAS 924296-17-3 DUBs-IN-3

DUBs-IN-3
(CAS: 924296-17-3)

DUBs-IN-3 is a potent deubiquitinase enzyme inhibitor for USP8. It is 30 fold selectivity over USP7.

CAS 63388-44-3 SJB2-043

SJB2-043
(CAS: 63388-44-3)

SJB2-043 is one of analogs/derivatives of C527, which is a novel and potent USP1 (ubiquitin-specific protease 1) inhibitor. It inhibited the Ub-VS labeling of a...

CAS 1247819-59-5 P22077

P22077
(CAS: 1247819-59-5)

P22077 is a potent and selective ubiquitin-specific protease 7 (USP7) inhibitor. P22077 potently induces apoptosis in NB cells with an intact USP7-HDM2-p53 axis...

CAS 924296-18-4 DUBs-IN-1

DUBs-IN-1
(CAS: 924296-18-4)

DUBs-IN-1 is a potent deubiquitinase enzyme inhibitor for USP7/USP8.

CAS 882257-11-6 P005091

P005091
(CAS: 882257-11-6)

P005091 is a potent and selective inhibitor of ubiquitin-specific protease (USP) 7 (IC50 = 4.2 μM). P005091 induces elevated p53 and apoptosis in cancer cell li...

CAS 924296-19-5 DUBs-IN-2

DUBs-IN-2
(CAS: 924296-19-5)

DUBs-IN-2 is a potent deubiquitinase enzyme inhibitor for USP7/USP8.

CAS 668467-91-2 LDN-57444

LDN-57444
(CAS: 668467-91-2)

LDN-57444 is a reversible, competitive proteasome inhibitor for UCH-L1 with IC50 of 0.88 μM, 28-fold greater selectivity over isoform UCH-L3.

Chemical Structure

CAS 1009817-63-3 b-AP15

Quick Inquiry

Verification code

Featured Items